KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Debt to Equity (2016 - 2020)

Nektar Therapeutics has reported Debt to Equity over the past 10 years, most recently at $0.39 for Q1 2020.

  • For Q1 2020, Debt to Equity rose 159.22% year-over-year to $0.39; the TTM value through Mar 2020 reached $0.39, up 159.22%, while the annual FY2019 figure was $0.18, 25.15% up from the prior year.
  • Debt to Equity for Q1 2020 was $0.39 at Nektar Therapeutics, up from $0.18 in the prior quarter.
  • Over five years, Debt to Equity peaked at $72.16 in Q2 2017 and troughed at -$880.47 in Q1 2016.
  • A 5-year average of -$46.97 and a median of $0.17 in 2019 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: plummeted 54551.96% in 2016 and later soared 1267.67% in 2017.
  • Year by year, Debt to Equity stood at $2.76 in 2016, then grew by 1.06% to $2.79 in 2017, then plummeted by 94.85% to $0.14 in 2018, then increased by 25.15% to $0.18 in 2019, then surged by 118.17% to $0.39 in 2020.
  • Business Quant data shows Debt to Equity for NKTR at $0.39 in Q1 2020, $0.18 in Q4 2019, and $0.17 in Q3 2019.